Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Intangibles (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Intangibles for 14 consecutive years, with $1.5 million as the latest value for Q1 2026.

  • Quarterly Intangibles changed 0.0% to $1.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Jan 2026, changed 0.0% year-over-year, with the annual reading at $1.5 million for FY2025, 0.0% changed from the prior year.
  • Intangibles for Q1 2026 was $1.5 million at PharmaCyte Biotech, roughly flat from $1.5 million in the prior quarter.
  • The five-year high for Intangibles was $3.5 million in Q1 2022, with the low at $1.5 million in Q2 2024.
  • Average Intangibles over 5 years is $2.6 million, with a median of $3.5 million recorded in 2022.
  • The sharpest move saw Intangibles changed 0.0% in 2022, then crashed 56.35% in 2024.
  • Over 5 years, Intangibles stood at $3.5 million in 2022, then changed by 0.0% to $3.5 million in 2023, then plummeted by 56.35% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
  • According to Business Quant data, Intangibles over the past three periods came in at $1.5 million, $1.5 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.